Clinical trials: Phosphorus Metabolism
Chronic Kidney Disease, Dialysis
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00772382
- Testing
- MCI-196
- Where
- 21 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Tanabe Pharma Corporation
Hyperphosphatemia, End Stage Renal Disease
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP >2.5 and ≤4.5 mg/dL) in patients with…
- Trial name
- NORMALIZE (NCT03988920)
- Testing
- Tenapanor, Sevelamer Carbonate
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Ardelyx
Iron Deficiency Anaemia, Iron Deficiency Anemia
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
- Trial name
- NCT03237065
- Testing
- Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Pharmacosmos A/S
Hyperphosphatemia, End-stage Renal Disease
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.
- Trial name
- NCT00648167
- Testing
- ferric citrate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Keryx Biopharmaceuticals
Hemodialysis, Hyperphosphatemia
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia
- Trial name
- NCT01850602
- Testing
- PA21, Sevelamer hydrochloride
- Where
- Japan
- Volunteers
- 213 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Hyperphosphatemia, End-stage Renal Disease
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD).
- Conditions
- Hyperphosphatemia, End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
- Trial name
- NCT00967993
- Testing
- ferric citrate
- Where
- 3 sites in Israel
- Volunteers
- 22 people
- Sponsor
- Keryx Biopharmaceuticals
Control
Racial Differences in Phosphorus Metabolism
The investigators aim to study potential racial differences in renal phosphorus handling by provocatively testing urinary phosphorus excretion using parathyroid hormone infusions in healthy white volunteers compared to healthy…
- Trial name
- NCT00856726
- Testing
- 1-34 parathyroid infusion
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Miami
Tumor-Induced Osteomalacia, Oncogenic Osteomalacia
BGJ398 for the Treatment of Tumor-Induced Osteomalacia
Background: People with tumor-induced osteomalacia (TIO) have small tumors that may cause low blood phosphorus, weak muscles, bone pain, and broken bones. The tumors may be so small they are hard to find or impossible to remove.
- Trial name
- NCT03510455
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Hyperphosphatemia
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
This is a randomized, double-blind, placebo-controlled study to evaluate the effect of tenapanor on change in s-P levels when tenapanor is administered orally, twice daily for 28 days as adjunctive therapy to ESRD subjects with…
- Trial name
- NCT03824587
- Testing
- Tenapanor, Phosphate Binder Agents
- Where
- 48 sites in United States
- Volunteers
- 236 people
- Sponsor
- Ardelyx
End Stage Renal Disease, Hyperphosphatemia
A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis is 10-100 times higher than the normal population.
- Conditions
- End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
- Trial name
- NCT02661295
- Testing
- Ferric Citrate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Winthrop University Hospital
X-linked Hypophosphatemia
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
- Trial name
- NCT01340482
- Testing
- KRN23
- Where
- 6 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia
Long-term Effect of Lanthanum Carbonate on Bone
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an…
- Trial name
- NCT00557323
- Testing
- Lanthanum carbonate
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 34 people
- Sponsor
- Shire
Hyperphosphatemia, Kidney Disease
Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the loss of excretory function of the kidney.
- Trial name
- NCT00660530
- Testing
- Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Illinois at Chicago
Hemodialysis Patients With Hyperphosphatemia
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.
- Trial name
- NCT01833494
- Testing
- PA21
- Where
- Japan
- Volunteers
- 161 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Chronic Kidney Disease, Dialysis
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
This is a PIII multi-center, open-label, flexible dose, long-term safety study, that in conjunction with the E07(NCT00416520), E08(NCT00542386) and E09(NCT00451295) studies will allow exposure to MCI-196 for up to 52 weeks
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00542815
- Testing
- MCI-196, Another Phosphate binder (Sevelamer)
- Where
- 115 sites in Austria, Czechia and 13 more
- Volunteers
- 632 people
- Sponsor
- Tanabe Pharma Corporation
Iron Deficiency, Iron Deficiency Anemia
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
The purpose of this study is to determine if KRX-0502 (ferric citrate) is a safe and effective treatment for the management of serum phosphorus levels and iron deficiency in anemic chronic kidney disease (CKD) stage 3-5 subjects…
- Trial name
- NCT01736397
- Testing
- Ferric Citrate
- Where
- 20 sites in United States
- Volunteers
- 149 people
- Sponsor
- Keryx Biopharmaceuticals
Chronic Kidney Disease, Hyperphosphatemia
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a…
- Trial name
- NCT00416520
- Testing
- MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Another phosphate binder (Sevelamer)
- Where
- 68 sites in Australia, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- Tanabe Pharma Corporation
Osteoporosis, Osteopenia
Adding Phosphorus to Osteoporosis Drug Treatment
Osteoporosis causes bones to weaken and break more easily. Calcium and phosphorus are two minerals that are essential for normal bone formation.
- Trial name
- NCT00074711
- Testing
- Calcium carbonate, Calcium Phosphate
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- Creighton University
X-Linked Hypophosphatemia
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
The primary objectives of this study are to: Assess the long-term safety of KRN23 subcutaneous (SC) administration in adult subjects with XLH Assess the proportion of subjects achieving serum phosphorus levels in the normal range…
- Trial name
- NCT02312687
- Testing
- KRN23
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Kyowa Kirin, Inc.
Hyperphosphatemia
A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia
This is a Phase 3, Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients…
- Trial name
- NCT02688764
- Testing
- PA21 (Velphoro®), Calcium Acetate (Phoslyra®)
- Where
- 38 sites in United States, France and 5 more
- Volunteers
- 85 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma